S2Medical ABFRA:S21 ROE % is 0.00% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 797 Medical Devices & Instruments companies, S2Medical AB ranks worse than 53.83% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. S2Medical AB's annualized net income for the quarter that ended in Dec. 2025 was €0.00 Mil. S2Medical AB's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €1.31 Mil. Therefore, S2Medical AB's annualized ROE % for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for S2Medical AB's ROE % or its related term are showing as below:
FRA:S21'
s ROE % Range Over the Past 10 Years
Min: -520.39 Med: -62.16 Max: 47.22
Current: 1.03
During the past 10 years, S2Medical AB's highest ROE % was 47.22%. The lowest was -520.39%. And the median was -62.16%.
FRA:S21's ROE % is ranked worse than 53.83% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs FRA:S21: 1.03
S2Medical AB (FRA:S21) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
S2Medical AB ROE % Related Terms
S2Medical AB ROE % Historical Data
* Premium members only.
The historical data trend for S2Medical AB's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, S2Medical AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
S2Medical AB ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, S2Medical AB's ROE % distribution charts can be found below:
* The bar in red indicates where S2Medical AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
S2Medical AB (FRA:S21) has a ROE % of 0.00% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on S2Medical AB and its competitors. According to the industry distribution chart, S2Medical AB ranks #429 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 53.8%.
Is S2Medical AB's ROE % too high?
S2Medical AB's current ROE % is 0.00%. Based on the distribution chart, S2Medical AB ranks #429 out of 797 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does S2Medical AB's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, S2Medical AB ranks #429 out of 797 companies for ROE %. This places S2Medical AB in the lower half of its industry. The industry median ROE % is 2.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on S2Medical AB and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. S2Medical AB's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is S2Medical AB stock overvalued right now?
S2Medical AB (FRA:S21) has a current ROE % of 0.00%. The current ROE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For S2Medical AB (FRA:S21), the current ROE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
S2Medical AB is a research-intensive MedTech company from Sweden. The company develops products within the entire wound healing process from debridement and granulation to re-epithelialization. products for the initial phase of a wound's healing process until the end, when the wound is completely healed. S2Medical also has in its portfolio the product NoSmell for odor removal which is procured in several different Swedish healthcare regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S21 has been successfully added to your 